NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.07. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Myovant Sciences.

8 brokerages have issued 12 month target prices for Myovant Sciences' shares. Their forecasts range from $20.00 to $34.00. On average, they anticipate Myovant Sciences' stock price to reach $26.00 in the next year. This suggests a possible upside of 105.9% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

News stories about MYOV stock have been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myovant Sciences earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Myovant Sciences.

Myovant Sciences saw a decrease in short interest in December. As of December 13th, there was short interest totalling 2,860,000 shares, a decrease of 8.9% from the November 28th total of 3,140,000 shares. Based on an average daily volume of 2,470,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 9.0% of the shares of the stock are sold short. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), SAGE Therapeutics (SAGE), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Intra-Cellular Therapies (ITCI), Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Fate Therapeutics (FATE) and Intercept Pharmaceuticals (ICPT).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was acquired by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $12.63.

Myovant Sciences has a market capitalization of $1.13 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

The official website for Myovant Sciences is http://www.myovant.com/.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]